Treatment of myelodysplastic syndromes.
Stadler
Michael
M
Ganser
Arnold
A
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D001803:Blood Transfusion; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D013792:Thalidomide; D000077269:Lenalidomide